Immune Control of Tumors by Antigen Presentation Improvement

Tumor Biology

Volumn 24, Issue 5, 2003, Pages 228-235

  Remedi, María Mónica ^a,b   Bonacci, Gustavo ^a   Vides, Miguel Angel ^a   Donadio, Ana Carolina ^a  

^a UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^b Facultad de Ciencias Químicas   (Argentina)

Author keywords

Immune regulation; Major histocompatibility complex

Indexed keywords

ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; BIOASSAY; BREAST SARCOMA; CONTROLLED STUDY; FEMALE; GENETIC TRANSFECTION; GROWTH RATE; IMMUNE RESPONSE; INOCULATION; LABORATORY; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; RAT; TUMOR; TUMOR CELL LINE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MODEL; TUMOR REGRESSION; ULCER; WILD TYPE;

EID: 1542313849     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000076137     Document Type: Article

References (36)

1. Cormier JN, Panelli MC, Hackett JA, Bettinotti MP, Mixon A, Wunderlich J, Parker LL, Restifo NP, Ferrone S, Marincola FM: Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model. Int J Cancer 1999;80:781-790.
2. Elliott BE, Carlow DA, Rodricks A, Wade A: Perspectives on the role of MHC antigens in normal malignant cell development. Adv Cancer Res 1989;53:181-245.
3. Goodenow RS, Vogel JM, Linsk RL: Histocompatibility antigens on murine tumors. Science 1985;230:777-783.
4. Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL: Natural history of HLA expression during tumor development. Immunol Today 1993;14:491-499.
5. Garrido F, Ruiz-Cabello F, Cabrera T, Pérez-Villar JJ, López-Botet M, Duggan-Keen M, Stern PL: Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997;18:89-95.
6. Zoller M, Strubel A, Hammerling G, Andrighetto G, Raz A, Ben Ze'ev A: Interferon-γ treatment of B16 melanoma cells: Opposing effects for non-adaptative and adaptative immune defense and its reflection by metastatic spread. Int J Cancer 1988;41:256-266.
7. Ferrone S, Marincola FM: Loss of HLA class I antigens by melanoma cells: Molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995;16:487-494.
8. Pujol Borrell R, Todd I, Londei M, Foulis A, Feldmann M, Bottazzo GF: Inappropriate major histocompatibility complex class II expression by thyroid follicular cells in thyroid autoimmune disease and by pancreatic beta cells in type I diabetes. Mol Biol Med 1986;3:159-165.
9. Pardoll D: New strategies for active immunotherapy with genetically engineered tumor cells. Curr Opin Immunol 1992;4:619-623.
10. Armstrong TD, Clements VK, Martin BK, Ting JP, Ostrand-Rosenberg S: Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc Natl Acad Sci USA 1997;94:6886-6891.
11. Mutti L, Valle MT, Balbi B, Orengo AM, Lazzaro A, Alciato P, Gatti E, Betta PG, Pozzi E: Primary human mesothelioma cells express class II MHC, ICAM-1 and B7-2 and can present recall antigens to autologous blood lymphocytes. Int J Cancer 1998;78:740-749.
12. Steimle V, Otten LA, Zufferey M, Mach B: Complementation cloning of an MHC class II deficiency (or bare lymphocyte syndrome). Cell 1993;75:135-146.
13. Chang CH, Flavell RA: Class II transactivator regulates the expression of multiple genes involved in antigen presentation. J Exp Med 1995;181:765-767.
14. Kern I, Steimle V, Siegrist CA, Mach B: The two novel MHC class II transactivators RFX5 and CIITA both control expression of HLA-DM genes. Int Immunol 1995;7:1295-1299.
15. Momburg F, Koch N, Moller P, Moldenhauer G, Butcher G, Hammerling GJ: Differential expression of Ia and Ia-associated invariant chain in mouse tissues after in vivo treatment with IFN-gamma. J Immunol 1986;136:940-948.
16. Pacheco-Rupil B, Depiante-Depaoli M, Hliba E: Induction of mammary tumors in Wistar rats by intragastric intubation and by intramammary injection of 9,10-dimethyl-1,2-benzanthracene. Cell Mol Biol 1987;33:469-475.
17. Nestel FP, Greene RN, Kichian K, Ponka P, Lapp WS: Activation of macrophage cytostatic effector mechanisms during acute graft-versus-host disease: Release of intracellular iron and nitric oxide-mediated cytostasis. Blood 2000;96:1836-1843.
18. Remedi MM, Hliba E, Demarchi M, Depiante-Depaoli M: Relationship between immune state and tumor growth rate in rats bearing progressive and non-progressive mammary tumors. Cancer Immunol Immunother 1998;46:350-354.
19. Monaco JJ: A molecular model of MHC class-I-restricted antigen processing. Immunol Today 1992;13:173-179.
20. Neefjes JJ, Ploegh HL: Intracellular transport of MHC class II molecules. Immunol Today 1992;13:179-184.
21. Freland S, Chambers BJ, Andersson M, Van Kaer L, Ljunggren HG: Rejection of allogeneic and syngeneic but not MHC class I-deficient tumor grafts by MHC class I-deficient tumor mice. J Immunol 1998;160:572-579.
22. Wintzer HO, Benzing M, von Kleist S: Lacking prognostic significance of β2-microglobulin, MHC class I and class II antigen expression in breast carcinomas. Br J Cancer 1990;62:289-295.
23. Algarra I, Cabrera T, Garrido F: The HLA crossroad in tumor immunology. Hum Immunol 2000;61:65-73.
24. Tanaka H, Yoshizawa H, Yamaguchi Y, Ito K, Kagamu H, Suzuki E, Gejyo F, Hamada H, Arakawa M: Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells. J Immunol 1999;162:3574-3582.
25. Liu Y, Zheng P: Is tumor expression of the major histocompatibility complex antigen required for T cell immune surveillance? Arch Immunol Ther Exp (Warsz) 2001;49 (suppl 2):S61-S64.
26. Patry Y, Douillard JY, Meflah K, Le Pendu J: Immunization against a rat colon carcinoma by sodium butyrate-treated cells but not by interleukin 2-secreting cells. Gastroenterology 1995;109:1555-1565.
27. Soos JM, Krieger JI, Stuve O, King CL, Patarroyo JC, Aldape K, Wosik K, Slavin AJ, Nelson PA, Antel JP, Zamvil SS: Malignant glioma cells use MHC class II transactivator (CIITA) promoters III and IV to direct IFN-gamma-inducible CIITA expression and can function as nonprofessional antigen presenting cells endocytic processing and CD4(+) T-cell activation. Glia 2001;36:391-405.
28. Kornbluth RS: The immunological potential of apoptotic debris produced by tumor cells and during HIV infection. Immunol Lett 1994;43:125-132.
29. Hughes J, Liu Y, Van Damme J, Savill J: Human glomerular mesangial cell phagocytosis of apoptotic neutrophils: Mediation by a novel CD36-independent vitronectin receptor/thrombospondin mechanism that is uncoupled from chemokine secretion. J Immunol 1997;158:4389-4397.
30. Savill J, Fadok V, Henson P, Haslett C: Phagocyte recognition of cells undergoing apoptosis. Immunol Today 1993;14:131-136.
31. Reiter I, Krammer B, Schwamerger G: Cutting Edge: Differential effect of apoptotic versus necrotic tumor cells on macrophage antitumor activities. J Immunol 1999;163:1730-1732.
32. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N: Consequences of cell death: Exposure to necrosis tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 2000;191:423-434.
33. Devitt A, Moffatt OD, Raykundalia C, Capra JD, Simmons DL, Gregory CD: Human CD14 mediates recognition and phagocytosis of apoptotic cells. Nature 1998;392:505-509.
34. Savill J: Recognition and phagocytosis of cells undergoing apoptosis. Br Med Bull 1997;53:491-508.
35. Speiser DE, Miranda R, Zakarian A, Bachmann MF, McKall-Faienza K, Odermatt B, Hanahan D, Zinkernagel RM, Ohashi PS: Self-antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: Implications for immunotherapy. J Exp Med 1997;186:645-653.
36. Ochsenbein AF, Klenerman P, Karrer U, Ludewig B, Pericin M, Hengartner H, Zinkernagel RM: Immune surveillance against solid tumor fails because of immunological ignorance. Proc Natl Acad Sci USA 1999;96:2233-2238.